Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan + octreotide LAR versus tolvaptan + placebo in ADPKD
2017-004701-40Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tolvaptan and octreotide in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Change in glomerular filtration rate. Started Sep 2019; status: completed.
02
Drugs
tolvaptanoctreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2017-004701-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004701-40.